Loading clinical trials...
Loading clinical trials...
A Phase II Study of Neoadjuvant Toripalimab Plus Platinum-based Doublet for Potentially Resectable Stage III Non-small Cell Lung Cancer
Conditions
Interventions
Albumin-bound paclitaxel, Carboplatin, Toripalimab
Locations
1
China
Sun Yat sen University cancer center
Guangzhou, Guangdong, China
Start Date
August 1, 2019
Primary Completion Date
July 30, 2026
Completion Date
July 30, 2026
Last Updated
May 6, 2021
NCT06066138
NCT07485114
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Hao Long
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions